Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed Shelbaya

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Future Oncology (London, England)|June 30, 2020
Rituximab biosimilars in hematologic malignancies: the need for a real-world approachPilar Nava-Parada, Ahmed Shelbaya, Chadi Nabhan
Applied Health Economics and Health Policy|January 28, 2021
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer PerspectivesJingyan Yang, Rongzhe Liu, Varun Ektare, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 6, 2020
Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database AnalysisCourtney Johnson, Jennifer Stephens, Christopher Walker, et al.
Plos One|January 20, 2021
Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database studyYu-Chen Yeh, Joseph C Cappelleri, Xiaocong L Marston, et al.
The American Journal of Managed Care|May 26, 2026
Biosimilar adoption and provider performance in Medicare value-based payment modelsBasit Chaudhry, Andrew Yue, Ahmed Shelbaya, et al.
Surgical Infections|December 11, 2012
Risk factors for mixed complicated skin and skin structure infections to help tailor appropriate empiric therapyMarya Zilberberg, Scott T Micek, Marin H Kollef, et al.
Neuropsychiatric Disease and Treatment|November 9, 2016
Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims dataCaitlyn T Solem, Ahmed Shelbaya, Yin Wan, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 25, 2021
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and PhysiciansJingyan Yang, Kelly Blinzler, Joshua Lankin, et al.
Advances in Therapy|June 1, 2019
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid ArthritisDipen Patel, Ahmed Shelbaya, Raymond Cheung, et al.
Future Oncology (London, England)|July 14, 2021
Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USAAhmed Shelbaya, John M Kelton, Jeffrey Thompson, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Future Oncology (London, England)|June 30, 2020
Rituximab biosimilars in hematologic malignancies: the need for a real-world approachPilar Nava-Parada, Ahmed Shelbaya, Chadi Nabhan
Applied Health Economics and Health Policy|January 28, 2021
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer PerspectivesJingyan Yang, Rongzhe Liu, Varun Ektare, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 6, 2020
Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database AnalysisCourtney Johnson, Jennifer Stephens, Christopher Walker, et al.
Plos One|January 20, 2021
Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database studyYu-Chen Yeh, Joseph C Cappelleri, Xiaocong L Marston, et al.
The American Journal of Managed Care|May 26, 2026
Biosimilar adoption and provider performance in Medicare value-based payment modelsBasit Chaudhry, Andrew Yue, Ahmed Shelbaya, et al.
Surgical Infections|December 11, 2012
Risk factors for mixed complicated skin and skin structure infections to help tailor appropriate empiric therapyMarya Zilberberg, Scott T Micek, Marin H Kollef, et al.
Neuropsychiatric Disease and Treatment|November 9, 2016
Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims dataCaitlyn T Solem, Ahmed Shelbaya, Yin Wan, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 25, 2021
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and PhysiciansJingyan Yang, Kelly Blinzler, Joshua Lankin, et al.
Advances in Therapy|June 1, 2019
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid ArthritisDipen Patel, Ahmed Shelbaya, Raymond Cheung, et al.
Future Oncology (London, England)|July 14, 2021
Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USAAhmed Shelbaya, John M Kelton, Jeffrey Thompson, et al.
Pageof 3